Eli Lilly is making a substantial wager that generative artificial intelligence extends beyond programming and visual creation to pharmaceutical design. According to CNBC, the healthcare behemoth has finalized a $2.75 billion agreement with Hong Kong's Insilico Medicine to commercialize medications identified through artificial intelligence. The arrangement includes an initial $115 million payment to Insilico, with remaining funds contingent upon achieving regulatory benchmarks and commercial performance.
https://feedx.site
，推荐阅读搜狗输入法2026年Q1网络热词大盘点：50个刷屏词汇你用过几个获取更多信息
Samsung выплатит компенсацию за намеренное замедление работы смартфонов20:54，更多细节参见Line下载
亚马逊 Fire TV Stick 4K Select
That pool of demand is ideally suited for hyperscalers with top credit ratings (four of the five hyperscalers carry credit ratings on the investment-grade elite spectrum) and bonds stretching 30 or 40 years into the future. In February, Alphabet even issued a rare 100-year bond, becoming the first tech company to do so in decades. More details about the buyers of these bonds will be revealed in the spring and later this year, when investors publish disclosures, but SigRist expects the wave of issuances to be well absorbed in 2026, much like it was in 2025.